Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Abstract Background Aripiprazole is a second-generation antipsychotic, efficacious in patients with schizophrenia during acute episodes. Due to its pharmacological profile, aripiprazole may be of interest in patients with specific clinical profiles who have not been studied extensively in randomised...

Descrición completa

Detalles Bibliográficos

Principais autores:	Pierre-Michel Llorca, Philippe Nuss, Éric Fakra, Isabelle Alamome, Dominique Drapier, Wissam El Hage, Renaud Jardri, Stéphane Mouchabac, Marc Rabbani, Nicolas Simon, Marie-Noëlle Vacheron, Jean-Michel Azorin
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2022-05-01
Series:	BMC Psychiatry
Assuntos:	Aripiprazole Schizophrenia Negative symptoms Cognition Addiction Pregnancy
Acceso en liña:	https://doi.org/10.1186/s12888-022-04008-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!